No Data
No Data
On June 19, Keji Pharmaceutical -B (02171.HK) spent HKD 3.98 million to repurchase 700,000 shares.
On June 19th, Keji Pharmaceutical-B (02171.HK) announced the repurchase of 700,000 shares for HKD 3.98 million.
On June 18, Koji Pharmaceutical spent approximately HKD 748,100 to repurchase 139,500 shares.
SciClone Pharmaceuticals B (02171) announced that it will spend approximately HKD 748,100 to repurchase 139,500 shares on June 18, 2024, with a repurchase price of HKD 5.24-5.42 per share.
On June 18th, Keji Pharmaceutical -B (02171.HK) bought back 139,500 shares for HKD 748,000.
On June 18th, Koji Pharmaceuticals-B (02171.HK) announced that it spent HKD 748,000 to buy back 139,500 shares.
Keji Pharmaceutical-B (02171.HK) presented updated research results on the Phase II clinical trial of Saikai II and the first human trial of CT071 at the 2024 EHA annual meeting.
On June 17, Gelunhui announced that the updated results of Saikai Xi (Zevo Kyolun Race Injection, product number: CT053, a self-targeting CAR-T cell product targeting BCMA) and CT071 (a self-targeting CAR -T cell candidate product targeting G protein-coupled receptor C group 5 member D (GPRC5D)) were reported at the 29th European Hematology Association ("EHA") Annual Meeting. The results of the Lumicar Study 1 of Saikai Xi have been reported on Central European Summer Time 2024.
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
On June 14, Keji Pharmaceutical B (02171) spent approximately HKD 2.3217 million to repurchase 397,500 shares.
Kehao Pharmaceutical-B (02171) announced that it will spend about 2.3217 million Hong Kong dollars on June 14, 2024...
No Data